Abstract:Background The inhibitory receptor NKG2A and the activating receptor NKG2C modulate the function of NK and CD8 T cells by recognizing the same ligand, HLA-E. NKG2A is selectively expressed on lymphocytes with cytolytic function, including NK cells, NKT cells, and a subset of CD8 T cells. The NKG2C - expressing subset of NK cells, also called 'adaptive NK,' displays an altered receptor profile and is associated with chronic virus infections. Likewise, the NKG2C + CD8 T cell population also expands in CMV-infected patients. Moreover, the NKG2C 'engager' has the potential to generate a strong antitumor response against various tumors. NKG2A blockade, in combination with other PD-1 antibody, has demonstrated some positive clinical activity; However, as a standalone therapy, inhibition of NKG2A and HLA-E appears to be poorly effective both in mouse tumor models and in clinical trials. Thus, we developed a dual targeting antibody ES015 that recognizes both NKG2A and NKG2C, by simultaneously inhibiting NKG2A function yet promoting NKG2C action, leading to better anti-tumor response. Methods NKG2A family member binding and cross-species reactivity were evaluated by ELISA and FACS. Binding affinity was determined by Octet Red. Blocking activity was determined by competition assay. In vitro functional activity was determined by NK cytotoxicity assay. The NKG2C - mediated activation was evaluated in Jurkat-NFAT reporter assay and NK activation. Epitope analysis was performed by competitive ELISA and HDX-MS. Lead clone was humanized via CDR grafting and back mutation screening. The effects of dual acting ES015 on the antitumor immune response were investigated in PBMC humanized mouse model. Results We report the generation and preclinical characterization of a novel mAb ES015 with dual targeting of NKG2A and NKG2C. ES015 binds NKG2A with a sub-nM affinity and reverses the inhibitory effect of the NKG2A/HLA-E interaction. We also show that ES015 increased the killing sensitivity in different presenting antigen systems by additional activation of NKG2C signaling. As a single agent ES015 enhanced the killing activity and cytokine secretion of NK when in co-culture with cancer cell lines. ES015 in combination with PD-1/L1 blocking agents resulted in superior anti-tumor activity in vivo. Conclusions ES015 appears to be a first-in-class antibody with dual targeting of NKG2A (inhibition) and NKG2C (activation). Our preclinical data suggested that dual target of NKG2A and NKG2C is more efficacious than targeting NKG2A alone. The dual targeting agent ES015, once entering the clinical trials, is hence expected to demonstrate superior clinical response in clinical trials.

A monoclonal antibody produced against Naked2.

Preparation and Application of Monoclonal Antibody Against Hndrg2

Study on the Preparation of the Immunotoxin 2E8-NCTD and Its Targeting Killing Effect in Vitro.

An Anti-Dlk1 Monoclonal Antibody Produced Using ELISA and Hybridoma Techniques.

Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy

Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

1151 Antibody-drug Conjugates Targeting CLDN18.2 for the Treatment of Solid Tumors

An engineered NKp46 antibody for construction of multi-specific NK cell engagers

498 ES015, a First-in-class NKG2A and NKG2C Dual-Targeting Antibody, Demonstrated Potent Anti-Tumor Immune Response

Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human NDPK-A

Preparation and Functional Identification of A Monoclonal Antibody Against the Recombinant Soluble Human Nkp30 Receptor

An anti-human ppGalNAcT-2 monoclonal antibody

Naked cuticle homolog 2 controls the differentiation of osteoblasts and osteoclasts and ameliorates bone loss in ovariectomized mice

Abstract 1343: BSI-111, a highly selective anti-CD16a monoclonal antibody with potent agonist activity for building a NK cell engager platform

A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells.

Neutralizing Monoclonal Antibody Against Dickkopf2 Impairs Lung Cancer Progression Via Activating NK Cells

Preparation and Characterization of Monoclonal Antibodies Against Nucleostemin, a Protein That Controls Cell Proliferation in Stem Cells and Cancer Cells

Developing a novel neutralizing monoclonal antibody against TrkB

An Anti-Double-Stranded Dna Monoclonal Antibody Induced By Tumor Cell-Derived Dna Inhibits The Growth Of Tumor In Vitro And In Vivo Via Triggering Apoptosis